CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES

CCTN - 避孕临床试验网络 - 女性站点

• 批准号: 8937251
• 负责人: LIVIA WAN
• 金额: $ 43.76万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2017-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8937251
• 关键词: Acetates; Adverse effects; Affect; Clinical; Clinical Practice Guideline; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contractor; Contracts; Dose; Drug Kinetics; Enrollment; Equipment; Estrogens; Female; Goals; Good Clinical Practice; Government; Hemorrhage; Human Resources; Institutional Review Boards; International; Methods; Modification; Monitor; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmacodynamics; Progesterone Receptors; Progestins; Protocols documentation; Qualifying; Records; Regimen; Regulation; Resolution; Risk; Safety; Services; Site; Thromboembolism; Time; Uterine Fibroids; Venous; Woman; Work; contraceptive efficacy; emergency contraception; follow-up; symposium

There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly for obese women. A new oral contraceptive agent consisting of a progesterone receptor modulator, which does not affect endogenous estrogen levels, has been developed. Ulipristal acetate (UPA) has been used in a single high dose for emergency contraception and has been used continuously for up to six months for treatment of uterine fibroids. Low dose continuous usage of oral UPA is anticipated to inhibit ovulation and provide an estrogen free, bleed free method of contraception.

有无雌激素避孕的需求，以降低静脉注射的风险 血栓栓塞症(VTE)，特别是对肥胖女性。一种新型口服避孕药 由孕激素受体调节剂组成，不影响内源性雌激素 层级，已经被开发出来。醋酸利普利酯(UPA)已用于单次大剂量治疗 紧急避孕措施，已连续使用长达六个月，用于治疗 子宫肌瘤。小剂量连续口服uPA有望抑制排卵和 提供一种无雌激素、无出血的避孕方法。